Trial Profile
A study evaluating disease activity trends after dose escalation of infliximab (Remicade): US Corrona registry.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 25 Jan 2017 New trial record